

RELIEF CLOSES CHF 10M PRIVATE PLACEMENT: THE ADVISORS

Posted on 24 March 2021



Category: [Capital Markets](#)

Tags: [Christian Leuenberger](#), [Christian Schneider](#), [Ex-Featured](#), [Manu Ferro](#), [Pestalozzi](#), [Peter Kühn](#), [Robert Bernet](#), [Severin Roelli](#), [Vischer](#)



RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, [has entered into a binding agreement](#) with a single healthcare-dedicated U.S. institutional investor to purchase in a private placement Relief shares of CHF 10m, to be delivered from Relief's treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders' pre-emptive rights. The transaction closed on 18 March 2021. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The advisors

VISCHER [advised Relief regarding the Swiss legal aspects of this transaction](#) with Akerman LLP advising on U.S. laws. The team led by partner Dr. Robert Bernet (Corporate/M&A - pictured right) comprised Dr. Peter Kühn (Counsel, Corporate/M&A) and Christian Schneider (Associate, Banking & Finance).

Pestalozzi advised H.C. Wainwright. The team [included](#) Christian Leuenberger (Lead Partner - Capital Markets, Corporate/M&A - pictured left), Severin Roelli (Partner - Corporate/M&A), Manu Ferro (Associate - Banking & Finance).